Learn more about the new KAPA HyperExome Probes

Utbildning i samarbete med KVAST-gruppen för bröstpatologi

Roche Sequencing Solutions is delighted to invite you to a virtual product training about the new KAPA HyperExome Probes
REGISTRERING

Agenda:

  • Klinisk betydelse av Her2-diagnostik inom bröstcancer
  • Riktlinjer (CAP 2015-2018) och rekommendationer för avläsning av Her2 IHC och dual ISH
  • Her2 IHC och dual ISH: kvalité och best practices
  • Fallgenomgång i grupp
  • Självständig fallgenomgång (på egen tid)

Del 2:

  • Fallgenomgång i grupp (svåra fall)
  • Q&A
REGISTRATION

Agenda

April 12th from 3:30 - 4:30pm


• Introducing the KAPA HyperCap Target Enrichment portfolio
• KAPA HyperExome Probes design strategy
• KAPA HyperExome Probes Performance data
• HyperDesign Tool and KAPA HyperCap custom designs
• Short hybridization performance data
• Q&A

 

Presenters: Markos Mihalatos PhD, Sr. International Product Manager Roche Sequencing Solutions


Moderator: Simona Carnielli, International Project Manager Roche Sequencing Solutions - Region EMEA-LATAM


An invitation to a Zoom meeting will be sent upon registration
REGISTRATION
Holger Sültmann
Division of Cancer Genome Research
German Cancer Consortium and German Cancer Research Center

Holger Sültmann graduated in biochemistry from Tübingen University and completed his PhD and assistant professorship at the Max-Planck-Institute for Biology (Tübingen). Currently, he is head of the Cancer Genome Research Division at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, and full professor at the Heidelberg University Medical Faculty. He has initiated and coordinated several interdisciplinary national and international cancer genome research projects, including the German contribution to prostate cancer genome sequencing in the International Cancer Genome Consortium. The current research focus of his division is on the application of high-throughput technologies to identify, characterize, and translate novel cancer biomarkers into the clinic, focusing on liquid biopsy approaches for early detection and therapy monitoring of cancer.

REGISTRATION

Registration